Multi-center, randomized, double-blind, placebo-controlled study of quetiapine extended-release formulation in Japanese patients with bipolar depression

Medicine and Dentistry

• Patient 70%
• Montgomery-Åsberg Depression Rating Scale 50%
• Adverse Event 30%
• Amaurosis 20%
• Spontaneous Remission 20%
• Monotherapy 20%
• Bipolar I Disorder 20%
• Bipolar II Disorder 20%
• Hamilton Rating Scale for Depression 20%
• Clinical Global Impression 20%
• Adult 10%
• Therapeutic Procedure 10%
• Placebo-Controlled Study 10%
• Depression 10%
• Somnolence 10%
• Rating Scale 10%
• Subgroup Analysis 10%
• Clinical Assessment 10%
• Atypical Antipsychotic 10%
• Mental Disorder 10%

Pharmacology, Toxicology and Pharmaceutical Science

• Placebo 100%
• Quetiapine 60%
• Bipolar Depression 40%
• Adverse Event 30%
• Blindness 20%
• Remission 20%
• Monotherapy 20%
• Bipolar I Disorder 20%
• Bipolar II Disorder 20%
• Placebo-Controlled Study 10%
• Atypical Antipsychotics 10%
• Somnolence 10%
• Depression 10%